Effect of Cyclosporine a on the Release of Tissue Factor Pathway Inhibitor from Endothelial Cells in Heart Transplant Patients and Cell Culture

Clinical Chemistry and Laboratory Medicine

Volumn 35, Issue 9, 1997, Pages 661-668

  Tiemann, Carsten ^a   Prohaska, Wolfgang ^a   Brinkmann, Thomas ^a   Kleesiek, Knut ^a   Körfer, Reiner ^a   Körner, Michael ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CALCIMYCIN; CREMOPHOR; CYCLOSPORIN A; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD DONOR; CELL CULTURE; DOSE RESPONSE; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CALCIMYCIN; CALCIUM; CELL DIVISION; CELLS, CULTURED; CYCLOSPORINE; ENDOTHELIUM, VASCULAR; FEMALE; GLYCEROL; HEART TRANSPLANTATION; HUMANS; IONOPHORES; LIPOPROTEINS; MALE; MIDDLE AGED; VEHICLES; VON WILLEBRAND FACTOR;

EID: 0030662184     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.1997.35.9.661     Document Type: Article

References (30)

1. Zoja C, Furei L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporine-induced endothelial cell injury. Lab Invest 1986; 55: 455-462.
2. Bossaller C, Förstermann K, Hertel R, Olbricht C, Reschke V, Fleck E. Cyclosporine A inhibits endothelium-dependent vasodilation and vascular prostacycline production. Eur J Pharmacol 1989; 165: 165-169.
3. Audi-Schwelk W, Bossaller C, Götze S, Thelen J, Fleck E. Endothelial and vascular smooth muscle function after chronic treatment with cyclosporine A. J Cardiovasc Pharmacol 1993; 21: 435-440.
4. DeCaterina R, Tanaka H, Nakagawa T, Hauptmann PJ, Libby P. The direct effect of injectable cyclosporine and its vehicle, cremophor, on endothelial vascular cell adhesion molecule-1 expression. Transplantation 1995; 60: 270-275.
5. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue factor pathway inhibitor and lipopolysaccha-rides-evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-229.
6. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb 1995; 15: 879-885.
7. Novotny WF, Girard TF, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor. Blood 1988; 76: 2020-2025.
8. Hamamoto T, Yamamoto M, Nordfang O, Listke Petersen J. G., Foster DC, Kisliel W. Inhibitory properties of full length and truncated recombinant tissue factor pathway inhibitor (TFPI). J Biol Chem 1993; 268: 8704-8712.
9. Sandset PM, Albigaard U, Larsen ML, Heparin induces release of extrinsic pathway inhibitor (EPI). Thromb Res 1988; 50: 803-809.
10. Legrand YJ, Rodrigues-Zeballos G, Kartalis G, Fauvel F, Caen JR, Adsorption of factor Vm antigen-activity complex by collagen. Thromb Res 1978; 13: 909.
11. Baumgartner HR, Tschopp TB, Meyer D. Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII von Willebrand factor. Br J Haematol 1980; 44: 127.
12. Stel HV, Sakariassen KS, DeGroot PG, van Mourik JA, Sixma JJ, von Willebrand factor in the vessel wall mediates platelet adherence. Blood 1985; 65: 85.
13. Boneu B, Abbal M, Plante J, Bienne R. Factor VII complex and endothelial damage. Lancet 1975; i: 1430.
14. Corda R, Alberti M, Caocci L, Putzolu G, Mannucci PM, An increased factor VIII antigen as an indicator of endothelial damage in measles. Thromb Res 1979; 14: 805.
15. Broze GJ, Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinol 1995; 6: S7.
16. Broze GJ, Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
17. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP, Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principle site of its synthesis. Proc Natl Acad Sei USA 1990; 87: 8869-8873.
18. Wam-Cramer BJ, Almus FE, Rapaport SI, Studies of the factor Xa-dependent inhibition of factor Vila/tissue factor (extrinsic pathway inhibitor) from cell supemates of cultured human umbilical vein endothelial cells. Thromb Haemost 1989; 61: 101-105.
19. Brinkmann T, Daum U, Tiemann C, Prohaska W, Kleesiek K. Improved chromogenic substrate assay of tissue factor pathway inhibitor (TFPI) using anti-TFPI antibodies and recombinant TFPI standard. Lab Med 1994; 9: 384.
20. Brinkmann T, Kähnert H, Prohaska W, Nordfang O, Kleesiek K. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophilacs. Eur J Clin Chem Clin Biochem 1994; 32: 313-317.
21. Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coag Fibrinol 1995; 6: 65-72.
22. Jeske W, Hoppenstedt D, Farred J, Bermes E. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some méthodologie considerations. Blood Coag Fibrinol 1995; 6: 73-80.
23. Brinkhouse KM, Sultzer DL, Reddick RL, Griggs TR, Elevated plasma von Willebrand factor (vWF) levels as an index of acute endothelial injury: use of hypotonic injury models in rats. Fed Prod 1980; 39: 630-642.
24. Holler E, Kolb HJ, Hiller E, Mraz W, Lehmacher W, Gleixner B, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018-24.
25. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
26. Hoppenstaedt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and low molecular weight heparin. Thromb Res 1995; 77: 175-185.
27. Abraham JS, Bentley RL, Garrison RN, Cryer HM, The influence of the cyclosporine vehicle, cremophor EL, on renal microvascular blood flow in the rat. Transplantation 1991; 52: 101-107.
28. Pfeilschifter J, Ruegg UT, Cyclosporine A augments angiotensin II stimulated rise in intracellular free calcium in vascular smooth muscle cells. J Biochem 1987; 248: 883-890.
29. Nicchitta C, Kamoun M, Williamson J. Cyclosporine A augments receptor-mediated cellular Ca2+ fluxes in isolated hepatocytes. J Biol Chem 1985; 260: 13613.
30. Pfeilschifter J. Cyclosporine A augments vasoconstrictor induced rise in intracellular free calcium in rat mesangial cells. Biochem Pharmacol 1988; 37: 4205.